Drugs / CIK cells
last change Mar 2026 re-read 2 minutes ago

CIK cells

Cell therapy

Developed for
colorectal cancer · non-small cell lung carcinoma · renal cell carcinoma · hepatocellular carcinoma · myelodysplastic syndrome · plasma cell myeloma · acute leukemia · acute myeloid leukemia
+33 more · cholangiocarcinoma · chronic myeloid leukemia · disease related to hematopoietic stem cell transplant · kidney cancer · lung cancer · nasopharyngeal carcinoma · small cell lung carcinoma · acute lymphoblastic leukemia · B-cell neoplasm · cancer · cancer of unknown primary site · cervical cancer · clear cell renal carcinoma · colonic neoplasm · colorectal carcinoma · digestive system cancer · esophageal cancer · esophageal squamous cell carcinoma · gastric cancer · Hodgkins lymphoma · leukemia · lung adenocarcinoma · melanoma · metastatic malignant neoplasm · neoplasm · neuroblastoma · ovarian carcinoma · pancreatic ductal adenocarcinoma · peritoneal neoplasm · pleural neoplasm · urinary bladder cancer · urinary bladder neoplasm · myeloproliferative neoplasm
Investigated by
The First People's Hospital of Changzhou · Affiliated Hospital to Academy of Military Medical Sciences · Sun Yat-sen University · People's Hospital of Guangxi Zhuang Autonomous Region · Singapore General Hospital · Tianjin Medical University Cancer Institute and Hospital
+44 more · Affiliated Hospital of Jiangnan University · Alliancells-PuRui Biocience Co., Ltd. · Allife Medical Science and Technology Co., Ltd. · American Society of Clinical Oncology · American Society of Hematology · Beijing Hospital · Belarusian State Medical University · Capital Medical University · China Meitan General Hospital · Digestive Diseases Research Institute, Tehran University of Medical Sciences, Iran · Everett Meyer · Fuzhou General Hospital · Gabrielle's Angel Foundation · Han weidong · Henan Cancer Hospital · Henan Provincial People's Hospital · Hunan Cancer Hospital · ImmunityBio, Inc. · Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus · Kunming Medical University · LucasBio · Mahidol University · Ministry of Health and Medical Education · National Cancer Institute (NCI) · National Institutes of Health (NIH) · National Medical Research Council (NMRC), Singapore · Peter Bader · Sabz Biomedicals · Sally Arai · Shenzhen Second People's Hospital · ShiCang Yu · Sichuan University · Siriraj Hospital · Stanford University · The First People's Hospital of Yunnan · The Leukemia and Lymphoma Society · University of Malaya · Washington University School of Medicine · West China Hospital · Wuxi People's Hospital · Xiaoyi Huang · Yanjuan Zhu · Zhejiang Provincial People's Hospital · Zhongyuan Union Stem Cell Bio-engineering Corporation

Trials 47 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT03815630 Feb 2019 → Feb 2020 neoplasm Allife Medical Science and Technology Co., Ltd. Unknown No outcome recorded
Phase 14 trials
Phase 1 NCT05268172 Dec 2022 → Dec 2024 pleural neoplasm Affiliated Hospital of Jiangnan University Unknown No outcome recorded
Phase 1 NCT01914263 Mar 2014 → Apr 2016 hepatocellular carcinoma, lung cancer, renal cell carcinoma Alliancells-PuRui Biocience Co., Ltd. Unknown No outcome recorded
Phase 1 NCT00477035 May 2006 → Mar 2011 leukemia, plasma cell myeloma Sally Arai Completed No outcome recorded
Phase 1 NCT00185757 Jun 2004 → Dec 2012 disease related to hematopoietic stem cell transplant, plasma cell myeloma Stanford University Completed No outcome recorded
Phase 1/214 trials
Phase 1/2 NCT05108077 Mar 2022 → Dec 2023 kidney cancer, urinary bladder cancer Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus Unknown No outcome recorded
Phase 1/2 NCT03329664 Feb 2020 → Sep 2021 colorectal carcinoma Sabz Biomedicals Unknown No outcome recorded
Phase 1/2 NCT03757858 Mar 2018 → Dec 2022 digestive system cancer, metastatic malignant neoplasm, peritoneal neoplasm Capital Medical University Completed No outcome recorded
Phase 1/2 NCT03047525 Feb 2017 → Jan 2019 colorectal cancer, lung cancer, nasopharyngeal carcinoma, renal cell carcinoma Xiaoyi Huang Unknown No outcome recorded
Phase 1/2 NCT02752243 Mar 2016 → Mar 2023 acute leukemia, myelodysplastic syndrome Peter Bader Unknown No outcome recorded
Phase 1/2 NCT01898793 Aug 2014 → Dec 2021 acute myeloid leukemia Washington University School of Medicine Terminated No outcome recorded
Phase 1/2 NCT02688673 Aug 2014 → Aug 2016 small cell lung carcinoma Affiliated Hospital to Academy of Military Medical Sciences Unknown No outcome recorded
Phase 1/2 NCT02693236 Aug 2014 → Aug 2016 esophageal cancer Affiliated Hospital to Academy of Military Medical Sciences Unknown No outcome recorded
Phase 1/2 NCT01956630 Sep 2013 → Sep 2016 acute leukemia Affiliated Hospital to Academy of Military Medical Sciences Unknown No outcome recorded
Phase 1/2 NCT01924156 Jul 2013 → Dec 2016 renal cell carcinoma Affiliated Hospital to Academy of Military Medical Sciences Unknown No outcome recorded
Phase 219 trials
Phase 2 NCT04836728 Mar 2021 → Apr 2024 overdue non-small cell lung carcinoma Tianjin Medical University Cancer Institute and Hospital Active not recruiting No outcome recorded
Phase 2 NCT03987698 Jun 2019 → Jun 2022 clear cell renal carcinoma Tianjin Medical University Cancer Institute and Hospital Unknown No outcome recorded
Phase 2 NCT03002831 Nov 2016 → Oct 2019 cancer of unknown primary site Henan Cancer Hospital Terminated No outcome recorded
Phase 2 NCT02489890 Feb 2016 → Jul 2025 overdue urinary bladder neoplasm The First People's Hospital of Changzhou Active not recruiting No outcome recorded
Phase 2 NCT02487550 Aug 2015 → Jul 2028 expected kidney cancer The First People's Hospital of Changzhou Not yet recruiting No outcome recorded
Phase 2 NCT02490735 Aug 2015 → Aug 2040 expected esophageal squamous cell carcinoma The First People's Hospital of Changzhou Not yet recruiting No outcome recorded
Phase 2 NCT02498756 Aug 2015 → Aug 2038 expected melanoma The First People's Hospital of Changzhou Not yet recruiting No outcome recorded
Phase 2 NCT02490748 Jul 2015 → Jun 2038 expected cervical cancer The First People's Hospital of Changzhou Active not recruiting No outcome recorded
Phase 2 NCT02493582 Jul 2015 → Jul 2030 expected lung adenocarcinoma The First People's Hospital of Changzhou Active not recruiting No outcome recorded
Phase 2 NCT02487992 Jul 2015 → Jul 2043 expected colorectal cancer The First People's Hospital of Changzhou Active not recruiting No outcome recorded
Phase 2/34 trials
Phase 2/3 NCT05955157 Jan 2023 → Dec 2024 pancreatic ductal adenocarcinoma University of Malaya Unknown No outcome recorded
Phase 2/3 NCT02482454 Jul 2012 → Jul 2030 expected cholangiocarcinoma The First People's Hospital of Changzhou Active not recruiting No outcome recorded
Phase 2/3 NCT02419677 Jan 2010 → Dec 2014 colorectal cancer The First People's Hospital of Changzhou Completed No outcome recorded
Phase 2/3 NCT01481259 Jan 2010 → Jan 2013 non-small cell lung carcinoma People's Hospital of Guangxi Zhuang Autonomous Region Unknown No outcome recorded
Phase 32 trials
Phase 3 NCT01749865 Oct 2008 → Sep 2014 hepatocellular carcinoma Sun Yat-sen University Completed No outcome recorded
Phase 3 NCT00769106 Jun 2008 → Sep 2014 hepatocellular carcinoma Sun Yat-sen University Completed No outcome recorded
Phase 41 trial
Phase 4 NCT03084809 May 2012 → Sep 2014 colorectal cancer China Meitan General Hospital Completed No outcome recorded
Phase not applicable2 trials
NCT05676190 Jan 2023 → Dec 2026 expected colorectal cancer ShiCang Yu Recruiting No outcome recorded
NCT07692607 Mar 2022 → Feb 2025 disease related to hematopoietic stem cell transplant LucasBio Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03282435 Comparator Jan 2018 → Jan 2023 non-small cell lung carcinoma Dalian University Unknown No outcome recorded
Phase 21 trial
Phase 2 NCT03524274 Comparator Apr 2018 → May 2020 colorectal cancer Fuda Cancer Hospital, Guangzhou Withdrawn No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 51 sources stand behind the page.

FieldValueCited text
Known as CIK cells “Cytokine-induced killer (CIK) cells are a heterogeneous population of effector CD8+ T cells with diverse TCR specificities, possessing non-MHC-restricted cytolytic activities...” PMID 24720900 Apr 2014
19

“Patients receive autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) by endermic injection and infusion of CIK cells.” NCT02487550

“ex vivo expanded autologous Cytokine-induced killer (CIK) cells as an adoptive cellular immunotherapy” NCT00815321

CIK cells: intravenous infusions; D14-16; one cycle every month,at least 6 cycles;” NCT01871480

CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1” NCT03524274

“infusion of CIK cellsNCT00862303

NCT00477035

NCT04836728

NCT03282435

NCT00460694

NCT02693236

NCT07692607

NCT01956630

NCT02688673

NCT01392989

NCT03987698

NCT02752243

NCT03815630

NCT01655628

NCT05268172

Known as Autologous cytokine-induced killer cell ClinicalTrials.gov intervention name — accepted as the source's own label NCT01592422
1

NCT01481259

Known as CIK “Combinations of Dendritic and Cytokine-induced Killer Cells (DC-CIK) and Cytokine-induced Killer Cells (CIK) treatment may enhance the immune response and stop cancer cells...” NCT03047525
10

CIK cells transfected with cytokine genes possess an improved proliferation rate and a higher cytotoxic activity as compared to regular CIK cells.” NCT02487992

“Immunotherapy with cytokine-induced killer cells (CIK) may improve tumor control and survival, as well as a better quality of life.” NCT01871480

“Cytokine induced killer cells ( CIK) characterized as fast amplification, strong anti-cancer activity and broad anti-tumor spectrum” NCT01533727

“Cytokine-induced killer (CIK) cells exhibit high proliferation rate and cytotoxic activity in vitro.” NCT01868490

“cytokine-induced killer (CIK) cells are an effective tool against various types of solid tumors” PMID 26842696 Feb 2016

“Treatment of Colorectal Cancer With Autologous Cytokine Induced Killer Cells (CIK)” NCT05676190

“chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment” NCT02489890

“cytokine-induced killer cell (CIK) treatment” NCT00769106

“cytokine-induced killer cells (CIK) therapy” NCT01929499

“Cytokine-Induced Killer Cell (CIK)” NCT02487550

Known as Cytokine-induced killer Cytokine-induced killer (CIK) cells are a heterogeneous population of effector CD8+ T cells with diverse TCR specificities, possessing non-MHC-restricted cytolytic activities...” PMID 24720900 Apr 2014
Known as cytokine-induced killer (CIK) cells “Thus, we aimed to find an innovative strategy to refine therapeutic applications and improve their outcomes by examining the potential of cytokine-induced killer (CIK) cells.” PMID 41520915 Jan 2026
1

“ex vivo expanded autologous Cytokine-induced killer (CIK) cells as an adoptive cellular immunotherapy” NCT00815321

Known as Cytokine-Induced Killer Cell Cytokine-Induced Killer Cell (CIK)” NCT02487550
5

NCT03329664

NCT01799083

NCT00769106

NCT05955157

NCT01914263

Known as cytokine-induced killer cells “CIK cells (cytokine induced killer cells, CIK) are a population of heterogeneous cells generated by the in vitro amplification of mononuclear cells in peripheral blood.” NCT01655628
25

“Immunotherapy with cytokine-induced killer cells (CIK) may improve tumor control and survival, as well as a better quality of life.” NCT01871480

“Cytokine induced killer cells ( CIK) characterized as fast amplification, strong anti-cancer activity and broad anti-tumor spectrum” NCT01533727

“cultured cytokine-induced killer cells for 15-20 days. Cells were infused back to the patients” NCT03757858

“Treatment of Colorectal Cancer With Autologous Cytokine Induced Killer Cells (CIK)” NCT05676190

“Treatment of Colorectal Cancer With Autologous Cytokine Induced Killer Cells (CIK)” NCT05676190

cytokine-induced killer cells (CIK) therapy” NCT01929499

NCT02490735

NCT02487693

NCT01929499

NCT03047525

NCT00185757

NCT02498756

NCT02493582

NCT02487992

NCT01898793

NCT03002831

NCT03084809

NCT02489890

NCT01749865

NCT02482454

NCT02419677

NCT01868490

NCT02490748

NCT05108077

NCT02485015

Action Deplete “Cytokine-induced killer ( CIK ) cells have been shown by our lab to be cytolytic against both autologous and allogeneic acute myeloid leukemia ( AML ) cells.” NCT00460694
Modality Cell therapy “use of activated T-cells to treat relapsed malignancy (cancer)” NCT00185757
Route Other “then infused into patients” NCT00460694